Abstract
There is a little data regarding safety or efficacy of monoclonal antibody treatment for mild-to-moderate COVID-19 in pediatric patients despite it being frequently used in adults. This retrospective study of 17 patients with mild-to-moderate COVID-19 who received monoclonal antibody therapy found that the treatment was well tolerated, safe, and may be effective in halting progression to severe disease.
All Keywords
【초록키워드】 COVID-19, Treatment, Efficacy, therapy, monoclonal antibody, progression, monoclonal antibody therapy, Retrospective study, Adults, Pediatric patients, Patient, monoclonal antibody treatment, severe disease, Mild-to-moderate, Safe, Pediatric patient, effective, 【제목키워드】 COVID-19, Safety,
【초록키워드】 COVID-19, Treatment, Efficacy, therapy, monoclonal antibody, progression, monoclonal antibody therapy, Retrospective study, Adults, Pediatric patients, Patient, monoclonal antibody treatment, severe disease, Mild-to-moderate, Safe, Pediatric patient, effective, 【제목키워드】 COVID-19, Safety,
{{{ 추상적인 }}}
성인에서 자주 사용되지만 소아 환자에서 경증에서 중등도의 COVID-19에 대한 단일 클론 항체 치료의 안전성이나 유효성에 대한 데이터가 거의 없습니다. 단일클론항체 요법을 받은 경증에서 중등도의 COVID-19 환자 17명을 대상으로 한 이 후향적 연구에서는 치료가 잘 견디고 안전하며 중증 질환으로의 진행을 멈추는 데 효과적일 수 있음을 발견했습니다.